Cancer Archives

roche cellsqueeze sqz cell therapies Cancer

News and Trends 9 Dec 2015

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

The MIT spin-off SQZ Biotech has an invention (Cell SQueeZe) which could make vector drug delivery in Cancer a thing of the past… Roche thinks so too, and has now acquired this small biotech for €455M upfront. MIT Professors Klavs Jensen, Robert Langer and PhD Student Armon Sharei were focused on developing a more effective system for […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Dec 2015

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

Wow! 55 of 59 patients in a Novartis trial experienced complete remission in one of the largest investigational CAR-T therapies for children with relapsed/refractory acute lymphoblastic leukemia (ALL). These are the latest findings from an ongoing phase II study of CTL019, an investigational chimeric antigen receptor T-cell (CAR-T) therapy, further support its potential in the […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Dec 2015

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Threshold Pharmaceuticals in the US has failed at getting its hypoxia prodrug evofosfamide through phase III trials for two types of cancer, and as a result has lost Merck’s partnership on the program. Evofosfamide (TH-302) is an investigational hypoxia-activated prodrug discovered by Threshold Pharmaceuticals in Pennsylvania (US). The prodrug is activated only at very low […]

December 8, 2015 - 2 minutesmins - By Dani Bancroft

morphosys multiple myeloma immunooncology mor202

News and Trends 7 Dec 2015

Best-in-Class Label for Blood Cancer Trial by Billion Euro Biotech

Latest results of MorphoSys candidate for Multiple Myeloma show that it was Celgene’s loss when it abandoned the phase I/IIa trial partnership on blood cancer. Announced at the American Society of Hematology (ASH) Annual Meeting this weekend in Orlando (US), the phase I/IIa drug for blood cancer from MorphoSys has shown good tolerability for this […]

December 7, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Dec 2015

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

This week we leave the old city of Oxford and travel South East across the channel, through France and arrive at our destination, Zurich, Switzerland. This wonderful city is famous for its many churches (including the Minster), the largest church clock in Europe, found on St Peter’s and is the home of many celebrities including […]

December 4, 2015 - 2 minutesmins - By Philip Hemme

kesios myeloma imperial innovations london

News and Trends 2 Dec 2015

An Imperial College Based Start-Up Has Raised €27M in Series A for a Blood Cancer Drug

Kesios is a start-up Biotech based in London (UK) which has raised over €27M in a Series A funding round for its pipeline targeting the fight against multiple myeloma. A syndicate of UK investors has jumped at the chance to fund this cancer-fighting biotech, whose nuclear factor kappa B (NF-κB)signal pathway targeting pipeline has promise […]

December 2, 2015 - 3 minutesmins - By Dani Bancroft

amgen leukemia blincyto antibody bispecific

News and Trends 1 Dec 2015

How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies

Blincyto (Blinatumomab) is the first bispecific antibody construct from Amgen’s BiTE proprietary platform to be granted clinical and regulatory validation so far… After the acquisition in 2012 of Micromet, the Munich-based company that first developed Blinatumomab, Amgen kept revealing the potential of this powerful protein… Blincyto was then approved by the FDA as an orphan […]

December 1, 2015 - 3 minutesmins - By Eva Cosson

News and Trends 30 Nov 2015

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

CAR-T is solidifying in everybody’s mind as the next revolution in Cancer treatment. But there is still a lot to do…That’s basically what came out from my discussion with André Choulika, the CEO of the French CAR-T miracle Cellectis. Cellectis is probably the most successful Biotech in France. It was founded in 1999 by Choulika […]

November 30, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 27 Nov 2015

Could this new TCR Lung Cancer Trial Save Adaptimmune from a Volatile Stock Situation?

Adaptimmune has initiated a phase I/II safety and tolerability study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with non-small cell lung cancer (NSCLC). Adaptimmune is developing the affinity enhanced T-cell therapy targeting the NY-ESO-1 antigen under a collaboration agreement with GlaxoSmithKline (GSK). Located in Oxford (UK) this clinical stage […]

November 27, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 27 Nov 2015

Biotech of the week: PsiOxus, “non-traditional” Immuno-oncology from Oxford

This week we leave Ireland and head South-East across the Irish Sea where we arrive at the ancient city of Oxford, our location of interest. ‘The city of dreaming spires’ is known for it’s world famous university, the Shark House (if you don’t know it, have a search, you won’t regret it :p) and the location for […]

November 27, 2015 - 2 minutesmins - By Philip Hemme

biosimilar war neulasta herceptin avastin rituxan1

News and Trends 25 Nov 2015

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Novartis is hitting back in the Biosimilar battleground: now Neulasta, the white blood cell booster for Cancer, is the latest of Amgen’s victims… Neulasta (pegfilgrastim) has been submitted through Novartis’ subsidiary, Sandoz. As a recombinant human granulocyte colony-stimulating factor (G-CSF), pegfilgrastim looks to stimulate the immune system and boost the white cell count. Neulasta is […]

November 25, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 24 Nov 2015

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

The World Leader in the Immuno-Oncology field has teamed up with a major German Investor to better identify breakthrough investment opportunities across the EU. Bristol-Myers Squibb (BMS) has partnered with Life Sciences Partners in Munich to highlight novel immuno-oncology technologies which could be the next blockbusters in the field. Together the two have conspired a […]

November 24, 2015 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Best-in-Class Label for Blood Cancer Trial by Billion Euro Biotech

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

An Imperial College Based Start-Up Has Raised €27M in Series A for a Blood Cancer Drug

How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

Could this new TCR Lung Cancer Trial Save Adaptimmune from a Volatile Stock Situation?

Biotech of the week: PsiOxus, “non-traditional” Immuno-oncology from Oxford

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!